In vitro interactions between primycin and different statins in their effects against some clinically important fungi

Journal of Medical Microbiology

Volumn 59, Issue 2, 2010, Pages 200-205

  Nyilasi, Ildikó ^a,b   Kocsubé, Sándor ^a,b   Pesti, Miklós ^c   Lukács, Gyöngyi ^b   Papp, Tamás ^b   Vágvölgyi, Csaba ^b  

^a PannonPharma Ltd   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c UNIVERSITY OF PÉCS   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; ATORVOX; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; MEVINOLIN; PRAVASTATIN; PRIMYCIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; VASILIP;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; CANDIDA GLABRATA; CONTROLLED STUDY; DILUTION; DRUG INHIBITION; DRUG SENSITIVITY; FUNGUS; FUNGUS GROWTH; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPPORTUNISTIC INFECTION; PAECILOMYCES; PAECILOMYCES VARIOTII; PRIORITY JOURNAL; RHIZOPUS ORYZAE; SENSITIVITY ANALYSIS; TITRIMETRY;

ANTIFUNGAL AGENTS; DRUG INTERACTIONS; FUNGI; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MACROLIDES; MICROBIAL SENSITIVITY TESTS;

EID: 76049124694     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.013946-0     Document Type: Article

References (32)

1. Afeltra, J. & Verweij, P. E. (2003). Antifungal activity of nonantifungal drugs. Eur J Clin Microbiol Infect Dis 22, 397-407.
2. Blaskó, K., Györgyi, S. & Horváth, I. (1979). Effect of primycin on monovalent cation transport of erythrocyte membrane and lipid bilayer. J Antibiot 32, 408-413.
3. Chamilos, G., Lewis, R. E. & Kontoyiannis, D. P. (2006). Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother 50, 96-103.
4. Chin, N. X., Weitzman, I. & Della-Latta, P. (1997). In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with fluconazole and itraconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother 41, 850-852.
5. Cordle, A., Koenigsknecht-Talboo, J., Wilkinson, B., Limpert, A. & Landreth, G. (2005). Mechanism of statin-mediated inhibition of small G-protein function. J Biol Chem 280, 34202-34209.
6. Galgóczy, L., Papp, T., Lukács, Gy., Leiter, É., Pócsi, I. & Vágvölgyi, Cs. (2007). Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive Zygomycetes. FEMS Microbiol Lett 270, 109-115.
7. Galgóczy, L., Kovács, L., Krizsán, K., Papp, T. & Vágvölgyi, Cs. (2009a). Inhibitory effects of cysteine and cysteine derivatives on germination of sporangiospores and hyphal growth of different Zygomycetes. Mycopathologia 168, 125-134.
8. Galgóczy, L., Nyilasi, I., Papp, T. & Vágvö lgyi, Cs. (2009b). Are statins applicable for the prevention and treatment of zygomycosis? Clin Infect Dis 49, 483-484.
9. Gisi, U. (1996). Synergistic interaction of fungicides in mixtures. Phytopathology 86, 1273-1279.
10. Gyetvai, Á., Emri, T., Takács, K., Dergez, T., Fekete, A., Pesti, M., Pócsi, I. & Lenkey, B. (2006). Lovastatin possesses a fungistatic effect against Candida albicans but does not trigger apoptosis in this opportunistic human pathogen. FEMS Yeast Res 6, 1140-1148.
11. Henderson, F. & Marshall, I. G. (1984). The effects of the antibiotic, primycin, on spontaneous transmitter release at the neuromuscular junction. Br J Pharmacol 81, 61-67.
12. Horvath, I., Kramer, M., Bauer, P. I. & Buki, K. G. (1979). The mode of action of primycin. Arch Microbiol 121, 135-139.
13. Kontoyiannis, D. P. (2007). Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin Infect Dis 44, 1089-1090.
14. Liao, J. K. & Laufs, U. (2005). Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45, 89-118.
15. Lorenz, R. T. & Parks, L. W. (1990). Effects of lovastatin (mevinolin) on sterol levels and on activity of azoles in Saccharomyces cerevisiae. Antimicrob Agents Chemother 34, 1660-1665.
16. Lukács, Gy., Papp, T., Nyilasi, I., Nagy, E. & Vágvölgyi, Cs. (2004). Differentiation of Rhizomucor species on the basis of their different sensitivities to lovastatin. J Clin Microbiol 42, 5400-5402.
17. Macreadie, I. G., Johnson, G., Schlosser, T. & Macreadie, P. I. (2006). Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol Lett 262, 9-13.
18. 2+ and permeability increase of the mitochondrial inner membrane by primycin. J Antibiot 33, 523-524.
19. Miida, T., Hirayama, S. & Nakamura, Y. (2004). Cholesterolindependent effects of statins and new therapeutic strategies: ischemic stroke and dementia. J Atheroscler Thromb 11, 253-264.
20. Natesan, S. K., Chandrasekar, P. H., Alangaden, G. J. & Manavathu, E. K. (2008). Fluvastatin potentiates the activity of caspofungin against Aspergillus fumigatus in vitro. Diagn Microbiol Infect Dis 60, 369-373.
21. NCCLS (1997). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, approved standard, document M27-A. Wayne, PA: National Committee for Clinical Laboratory Standards.
22. NCCLS (2002). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, approved standard, document M38-A. Wayne, PA: National Committee for Clinical Laboratory Standards.
23. Nucci, M. (2003). Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 16, 607-612.
24. Roze, L. V. & Linz, J. E. (1998). Lovastatin triggers an apoptosis-like cell death process in the fungus Mucor racemosus. Fungal Genet Biol 25, 119-133.
25. Schachter, M. (2005). Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19, 117-125.
26. Singh, N. (2001). Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 33, 1692-1696.
27. Sun, H.-Y. & Singh, N. (2009). Antimicrobial and immunomodulatory attributes of statins: relevance in solid-organ transplant recipients. Clin Infect Dis 48, 745-755.
28. Szabo, A. Z., Gaal, J. & Marmarosi, K., Sebestyen, G., Miholics, G. & Kovacs, M. (1993). Pharmaceutical compositions containing primycin. Patent EP0347225.
29. Uri, J. V. & Actor, P. (1979). Crystallization and antifungal activity of primycin. J Antibiot 32, 1207-1209.
30. Vályi-Nagy, T., Uri, J. & Szilágyi, I. (1954). Primycin, a new antibiotic. Nature 174, 1105-1106.
31. Walsh, T. J. & Groll, A. H. (1999). Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis 1, 247-261.
32. Walsh, T. J., Groll, A., Hiemenz, J., Fleming, R., Roilides, E. & Anaissie, E. (2004). Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 10 (Suppl. 1), 48-66.